AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 Intriguing Stocks Estimated At Up To 42.7% Below Intrinsic Value
Fri 23 May 25, 05:37 PM2 ‘Strong Buy’ Stocks That Are Crashing the Market in April
Wed 23 Apr 25, 10:01 AM3 Leading Stocks Estimated To Be Up To 45.9% Below Intrinsic Value
Fri 04 Apr 25, 05:07 PMUS High Growth Tech Stocks To Watch In April 2025
Wed 02 Apr 25, 11:08 AMSimulations Plus, Inc. (SLP): One of the Most Profitable Stocks According to Hedge Funds?
Sat 20 Jul 24, 01:25 PM| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Income before tax | 11.70M | 15.12M | 11.09M | 11.39M | 10.56M |
| Minority interest | - | - | - | - | - |
| Net income | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M |
| Selling general administrative | 34.72M | 24.96M | 20.57M | 16.36M | 11.80M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 47.95M | 43.08M | 35.87M | 30.94M | 24.94M |
| Reconciled depreciation | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M |
| Ebit | 4.88M | 11.34M | 7.86M | 8.89M | 10.65M |
| Ebitda | 8.72M | 14.91M | 11.45M | 11.85M | 13.43M |
| Depreciation and amortization | 3.84M | 3.57M | 3.59M | 2.96M | 2.78M |
| Non operating income net other | - | 0.20M | -0.14600M | -0.21813M | 0.02M |
| Operating income | 8.72M | 11.34M | 7.86M | 8.89M | 10.65M |
| Other operating expenses | 50.85M | 38.99M | 35.21M | 29.98M | 23.32M |
| Interest expense | 0.00000M | 0.72M | 0.02M | 2.50M | 0.11M |
| Tax provision | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M |
| Interest income | 4.13M | 0.72M | 0.20M | 0.03M | 0.03M |
| Net interest income | 4.13M | 0.72M | 0.18M | 0.03M | -0.07556M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M |
| Total revenue | 59.58M | 53.91M | 46.47M | 41.59M | 33.97M |
| Total operating expenses | 39.22M | 28.17M | 24.61M | 19.33M | 14.30M |
| Cost of revenue | 11.63M | 10.82M | 10.60M | 10.65M | 9.03M |
| Total other income expense net | 2.97M | 3.78M | 3.22M | 2.50M | -0.09225M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M |
| Net income applicable to common shares | - | 12.48M | 9.78M | 9.33M | 8.58M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Total assets | 186.10M | 188.38M | 179.98M | 168.42M | 45.20M |
| Intangible assets | 32.85M | 26.18M | 24.58M | 24.99M | 13.27M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.90M | 3.38M | 1.70M | 1.60M | 0.70M |
| Total liab | 16.07M | 10.13M | 14.20M | 12.39M | 7.52M |
| Total stockholder equity | 170.03M | 178.25M | 165.78M | 156.04M | 37.68M |
| Deferred long term liab | - | 1.46M | 1.73M | 2.35M | 2.73M |
| Other current liab | 8.30M | 4.18M | 10.15M | 4.25M | 3.40M |
| Common stock | 144.97M | 138.51M | 133.42M | 0.00993M | 0.00760M |
| Capital stock | 144.97M | 138.51M | 133.42M | 0.00993M | 0.00760M |
| Retained earnings | 25.20M | 40.04M | 32.41M | 27.44M | 22.35M |
| Other liab | - | 1.46M | 1.73M | 6.42M | 2.73M |
| Good will | 19.10M | 12.92M | 12.92M | 12.92M | 10.39M |
| Other assets | - | 0.44M | 0.05M | 18.96M | 0.04M |
| Cash | 57.52M | 51.57M | 36.98M | 49.21M | 11.44M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 11.99M | 7.74M | 11.57M | 5.50M | 4.78M |
| Current deferred revenue | 3.10M | 2.86M | 0.65M | 0.44M | 1.18M |
| Net debt | -56.32600M | -50.16300M | -35.70600M | -48.28054M | -11.43550M |
| Short term debt | 0.44M | 0.46M | 0.38M | 0.46M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.20M | 1.40M | 1.28M | 0.93M | - |
| Other stockholder equity | - | -0.30800M | 133.42M | 128.53M | 15.32M |
| Property plant equipment | - | 2.05M | 3.11M | 0.44M | 0.34M |
| Total current assets | 130.37M | 146.79M | 139.31M | 129.09M | 21.17M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 139.15M | 128.28M | 118.12M | 14.03M |
| Short term investments | 57.94M | 76.67M | 86.62M | 66.80M | - |
| Net receivables | 10.20M | 13.79M | 13.00M | 10.52M | 8.26M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.80M | 1.39M | 1.01M | 0.97M | 0.77M |
| Accounts payable | 0.14M | 0.23M | 0.39M | 0.35M | 0.20M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.14100M | -0.30800M | -0.04300M | 0.06M | -1.08313M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 138.51M | - | 0.00993M | 0.00760M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 40.04M | 32.41M | 27.44M | 22.35M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.42M | -1.01700M | 0.05M | 0.05M | 0.04M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 55.73M | 41.59M | 40.66M | 39.33M | 24.03M |
| Capital lease obligations | 1.20M | 1.40M | 1.28M | 0.93M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Investments | 7.37M | 8.28M | -22.16600M | -76.72028M | -1.95574M |
| Change to liabilities | - | 2.05M | 0.25M | -0.49525M | 0.72M |
| Total cashflows from investing activities | - | 4.30M | -26.74200M | -75.50571M | -1.95574M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -23.26600M | -7.62200M | -4.68400M | 102.37M | -7.64788M |
| Change to operating activities | - | -0.35600M | 3.25M | -0.37518M | 0.39M |
| Net income | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M |
| Change in cash | 5.96M | 14.58M | -12.22300M | 37.77M | 2.03M |
| Begin period cash flow | 51.57M | 36.98M | 49.21M | 11.44M | 9.40M |
| End period cash flow | 57.52M | 51.57M | 36.98M | 49.21M | 11.44M |
| Total cash from operating activities | 21.86M | 17.90M | 19.20M | 10.91M | 11.64M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 107.75M | - |
| Depreciation | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M |
| Other cashflows from investing activities | - | -3.15100M | -2.94900M | 1.45M | -1.81800M |
| Dividends paid | -4.80900M | -4.84600M | -4.81100M | -4.25047M | 4.20M |
| Change to inventory | 0.91M | - | 3.15M | -0.24725M | -1.30760M |
| Change to account receivables | 4.10M | -3.93600M | -2.42900M | -2.01779M | 0.49M |
| Sale purchase of stock | -20.00000M | -20.00000M | 1.46M | 108.38M | 0.79M |
| Other cashflows from financing activities | 1.54M | -3.66700M | 0.13M | -1.13128M | -3.45083M |
| Change to netincome | - | 4.46M | 4.86M | 1.40M | 0.89M |
| Capital expenditures | 4.27M | 3.97M | 4.58M | 2.58M | 1.96M |
| Change receivables | - | -3.93600M | -2.42900M | -1.87748M | -0.76009M |
| Cash flows other operating | - | 0.44M | -0.32400M | -0.41059M | -0.54639M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 14.58M | -12.22300M | 37.77M | 2.03M |
| Change in working capital | 5.10M | -2.62000M | 0.97M | -2.78332M | -0.58296M |
| Stock based compensation | 4.83M | 3.04M | 2.75M | 1.58M | 1.08M |
| Other non cash items | 0.22M | 1.70M | 2.73M | 0.20M | 0.11M |
| Free cash flow | 17.58M | 13.93M | 14.63M | 8.33M | 9.68M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SLP Simulations Plus Inc |
0.48 2.97% | 16.65 | 95.67 | 69.44 | 14.38 | 5.25 | 12.71 | 50.25 |
| VEEV Veeva Systems Inc Class A |
-0.12 0.07% | 178.60 | 54.61 | 33.22 | 12.83 | 6.73 | 11.14 | 58.84 |
| MTHRF M3 Inc |
- -% | 8.55 | 29.72 | 25.00 | 0.05 | 4.38 | 0.04 | 0.12 |
| MTHRY M3 Inc |
0.08 1.70% | 4.79 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
| BTSG BrightSpring Health Services, Inc. Common Stock |
-3.48 5.72% | 57.40 | 100.22 | 40.65 | 0.69 | 4.92 | 0.92 | 25.80 |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
42505 Tenth Street West, Lancaster, CA, United States, 93534-7059
| Name | Title | Year Born |
|---|---|---|
| Mr. Walter S. Woltosz M.A.S., M.S. | Co-Founder & Chairman | 1945 |
| Mr. Shawn M. O'Connor | Chief Exec. Officer | 1960 |
| Mr. John Anthony DiBella M.S. | Pres | 1980 |
| Mr. William Frederick | CFO & Sec. | 1964 |
| Dr. Brett A. Howell Ph.D. | Pres of DILIsym Services, Inc | 1984 |
| Ms. Jill Fiedler-Kelly M.S., MS | Pres of Cognigen Division | 1970 |
| Ms. Viera Lukacova Ph.D. | Chief Scientific Officer | NA |
| Dr. Bud Nelson J.D., Ph.D. | VP of Corp. Counsel & Personal Data Protection Officer | NA |
| Ms. Arlene Padron | Corp. Director of Marketing | NA |
| Ms. Lindsay Luke | Exec. Director of HR | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...